OphthalmologyNews.net

Ophthalmology Xagena

Search results for "Ranibizumab"

A Phase III clinical trial of the drug Ranibizumab ( Lucentis ) met its primary efficacy endpoint of maintaining vision in patients with wet age-related macular degeneration (AMD ). Approximately ...


A single-masked Phase I/II clinical study of the investigational drug Lucentis ( Ranibizumab ) met its primary efficacy endpoint of maintaining vision in patients with wet age-related macular degenera ...


Researchers from Boston University School of Medicine ( BUSM ) and the VA Boston Healthcare System have shown, at 6 months in a small group of patients, that there is no difference in efficacy between ...


The aim of the GEFAL trial was to evaluate the relative efficacy and safety profile of Bevacizumab ( Avastin ) versus Ranibizumab ( Lucentis ) intravitreal injections for the treatment of neovascular ...


Regeneron has announced that detailed one-year results from the VIEW 1 and VIEW 2 phase 3 studies of Aflibercept ( Eylea ) injection, published in the journal Ophthalmology. Eylea, for the treatmen ...


A single-practice retrospective chart review has reported on long-term visual outcomes in patients receiving continuous fixed-interval dosing of anti-vascular endothelial growth factor ( VEGF ) treatm ...


The purpose of a study was to evaluate the effect of monthly intravitreal Ranibizumab ( Lucentis ) on hard exudate ( HE ) area and the impact of hard exudate on visual acuity ( VA ) outcomes in diabet ...